Search
forLearn
5 / 801 resultslearn octapeptide-2
learn sh-Polypeptide-7
learn vitamin d2
learn Ceramide A2
Research
5 / 352 results
research Recent positive selection of a human androgen receptor/ectodysplasin A2 receptor haplotype and its relationship to male pattern baldness
A specific genetic mutation may increase male pattern baldness risk, especially in Europeans.
research Increased expression of Ectodysplasin A2 Receptor EDA2R is the most remarkable and ubiquitous aging-related transcriptional hallmark
The most common sign of aging at the gene level is more Ectodysplasin A2 Receptor (EDA2R) being made.
research A review of genetic researches of and rogenic alopecia
Male pattern baldness is partly caused by specific genes, but most genetic factors are still unknown.
research Genetic and molecular aspects of androgenetic alopecia
Androgenetic alopecia is mainly caused by genetic factors and increased androgen activity, leading to hair follicle miniaturization.
research Genetics of Alopecia
Different genes are linked to various types of hair loss.
Community Join
5 / 1000+ resultscommunity New and Interesting HairLoss Studies/Papers/Reviews
Hair loss treatments discussed include Dutasteride with Ketoconazole, tissue engineering strategies, and androgenetic alopecia therapies. Massage doubles follicular retention, improving treatment effectiveness.
community Protac degradation of the androgen receptor in mice shows good efficacy and no systemic drug could be found
The efficacy of degrading the androgen receptor through dermal application in DP cells, a delivery system for topical drugs that involves dissolving microneedles, and rosemary oil as an alternative anti-androgen.
community CRISPR treatment for AGA on the horizon after approval for blood disorders
CRISPR treatments for blood disorders have been approved, leading to discussions about its potential for treating hair loss (AGA). A study showed that editing a gene related to DHT sensitivity could lead to hair regrowth, suggesting CRISPR may eventually be used for AGA, but it's expected to be expensive and not soon available.
community Trial for TDM-105795 update from research office
The trial for TDM-105795 has been completed, and it was in phase 2A. The discussion seeks input on the next phases, 2B or 3, based on safety and efficacy.
community Phase II for Technoderma Therepeutic's TDM-105795 set to begin in April tentatively
Phase II for TDM-105795 for Androgenic Alopecia is set to begin in April 2023. The study aims to evaluate the efficacy and safety of TDM-105795 in male subjects.